Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021

Table of Contents

1 INTRODUCTION 16

1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.2.1 MARKET SEGMENTATION 17
1.2.2 YEARS CONSIDERED FOR THE STUDY 18
1.3 CURRENCY 18
1.4 LIMITATION 18
1.5 MARKET STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19

2.1 MARKET SIZE ESTIMATION 21
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.3 MARKET SHARE ESTIMATION 24
2.4 KEY DATA FROM SECONDARY SOURCES 24
2.5 KEY DATA FROM PRIMARY SOURCES 25
2.6 KEY INDUSTRY INSIGHTS 25
2.7 ASSUMPTIONS FOR THE STUDY 26

3 EXECUTIVE SUMMARY 27

3.1 INTRODUCTION 27
3.2 CURRENT SCENARIO 27
3.3 FUTURE OUTLOOK 28
3.4 CONCLUSION 30

4 PREMIUM INSIGHTS 31

4.1 GLOBAL VACCINES MARKET 31
4.2 VACCINES MARKET, BY TYPE 32
4.3 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY END USER 32
4.4 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY 33
4.5 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 34
4.6 LIFECYCLE ANALYSIS, BY REGION, 2016 35
 

5 MARKET OVERVIEW 36

5.1 INTRODUCTION 37
5.2 MARKET SEGMENTATION 37
5.3 MARKET DYNAMICS 38
5.3.1 DRIVERS 39
5.3.1.1 High prevalence of diseases 39
5.3.1.2 Rising government and non-government funding for vaccine development 39
5.3.1.3 Increasing investments by companies 41
5.3.1.4 Increasing government focus on immunization programs 41
5.3.2 RESTRAINTS 42
5.3.2.1 Huge capital investments 42
5.3.2.2 Stringent regulations 43
5.3.3 OPPORTUNITIES 43
5.3.3.1 High growth prospects in emerging markets 43
5.3.3.2 Therapeutic vaccines 44
5.3.3.3 Adjuvant vaccines 44
5.3.4 CHALLENGES 45
5.3.4.1 Inadequate access to vaccines 45
5.3.4.2 Vaccine pricing 46
5.3.5 BURNING ISSUES 46
5.3.5.1 Vaccine failure 46
5.4 INVESTMENT ANALYSIS 47
5.5 REGULATORY LANDSCAPE 49
5.5.1 NORTH AMERICA 50
5.5.2 EUROPE 51
5.5.3 ASIA 52
5.5.4 ROW 52
5.6 PATENT ANALYSIS 53
5.7 KEY PIPELINE PRODUCTS 55

6 VACCINES MARKET, BY TECHNOLOGY 57

6.1 INTRODUCTION 58
6.2 CONJUGATE VACCINES 59
6.3 INACTIVATED AND SUBUNIT VACCINES 60
6.4 LIVE ATTENUATED VACCINES 62
6.5 TOXOID VACCINES 63
6.6 RECOMBINANT VACCINES 64
 

7 VACCINES MARKET, BY TYPE 66

7.1 INTRODUCTION 67
7.2 MONOVALENT VACCINES 68
7.3 MULTIVALENT VACCINES 69

8 VACCINES MARKET, BY DISEASE INDICATION 71

8.1 INTRODUCTION 72
8.2 PNEUMOCOCCAL DISEASE 73
8.3 DTP 74
8.4 INFLUENZA 75
8.5 HUMAN PAPILLOMA VIRUS 77
8.6 MENINGOCOCCAL DISEASE 78
8.7 POLIO 80
8.8 ROTAVIRUS 81
8.9 HEPATITIS 82
8.10 MMR 83
8.11 VARICELLA 84
8.12 OTHERS 85

9 VACCINES MARKET, BY END USER 87

9.1 INTRODUCTION 88
9.2 PEDIATRICS 89
9.3 ADULTS 90

10 VACCINES MARKET, BY REGION 92

10.1 INTRODUCTION 93
10.2 NORTH AMERICA 95
10.2.1 U.S. 98
10.2.2 CANADA 100
10.3 EUROPE 101
10.3.1 GERMANY 104
10.3.2 U.K. 105
10.3.3 FRANCE 106
10.3.4 ITALY 107
10.3.5 SPAIN 108
10.3.6 REST OF EUROPE (ROE) 109
10.4 ASIA 110
10.4.1 JAPAN 113
10.4.2 CHINA 114
10.4.3 INDIA 115
10.4.4 REST OF ASIA (ROA) 116
10.5 REST OF THE WORLD (ROW) 117

11 COMPETITIVE LANDSCAPE 120

11.1 OVERVIEW 120
11.2 MARKET SHARE ANALYSIS 121
11.3 COMPETITIVE SITUATION AND TRENDS 122
11.3.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 123
11.3.2 REGULATORY APPROVALS 124
11.3.3 ACQUISITIONS 125
11.3.4 EXPANSIONS 125
11.3.5 OTHER DEVELOPMENTS 126

12 COMPANY PROFILES 127

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 INTRODUCTION 127
12.2 PFIZER, INC. 128
12.3 GLAXOSMITHKLINE, PLC. 131
12.4 MERCK & CO., INC. 135
12.5 SANOFI PASTEUR 137
12.6 CSL LIMITED 140
12.7 EMERGENT BIOSOLUTIONS, INC. 142
12.8 JOHNSON & JOHNSON 144
12.9 MEDIMMUNE, LLC. (A SUBSIDIARY OF ASTRAZENECA) 146
12.10 ASTELLAS PHARMA INC. 148
12.11 SERUM INSTITUTE OF INDIA 150

13 APPENDIX 151

LIST OF TABLES

TABLE 1 INCIDENCE OF DISEASES, 2014-2015 39
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2012-2016 (USD MILLION) 40
TABLE 3 HIGH PREVALENCE OF DISEASES TO BOOST THE VACCINES MARKET 42
TABLE 4 HUGE CAPITAL INVESTMENTS TO LIMIT THE MARKET GROWTH OF VACCINES 43
TABLE 5 HIGH GROWTH POTENTIAL IN EMERGING COUNTRIES TO BOOST THE MARKET FOR VACCINES 44
TABLE 6 IMMUNIZATION COVERAGE, BY DISEASE, 2014 45
TABLE 7 INADEQUATE ACCESS TO VACCINES A MAJOR CHALLENGE IN THE MARKET 46
TABLE 8 REGULATORY AUTHORITIES IN EUROPE 51
TABLE 9 REGULATORY AUTHORITIES IN ASIA 52
TABLE 10 KEY PIPELINE VACCINES 55
TABLE 11 VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 58
TABLE 12 CONJUGATE VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 59
TABLE 13 EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES 61
TABLE 14 INACTIVATED AND SUBUNIT VACCINES MARKET SIZE, BY REGION,
2014–2021 (USD MILLION) 61
TABLE 15 LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION,
2014–2021 (USD MILLION) 63
TABLE 16 TOXOID VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 63
TABLE 17 RECOMBINANT VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 65
TABLE 18 VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 67
TABLE 19 MONOVALENT VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 68
TABLE 20 EXAMPLES OF MULTIVALENT VACCINES 69
TABLE 21 MULTIVALENT VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 70
TABLE 22 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD MILLION) 72
TABLE 23 LIST OF PNEUMOCOCCAL VACCINES 73
TABLE 24 VACCINES MARKET SIZE FOR PNEUMOCOCCAL DISEASE, BY REGION,
2014–2021 (USD MILLION) 73
TABLE 25 LIST OF DTP VACCINES 74
TABLE 26 VACCINES MARKET SIZE FOR DTP, BY REGION, 2014–2021 (USD MILLION) 74
TABLE 27 LIST OF INFLUENZA VACCINES 75
TABLE 28 VACCINES MARKET SIZE FOR INFLUENZA, BY REGION, 2014–2021 (USD MILLION) 76
TABLE 29 LIST OF HPV VACCINES 77
TABLE 30 VACCINES MARKET FOR HPV, BY REGION, 2014–2021 (USD MILLION) 77
TABLE 31 LIST OF MENINGOCOCCAL VACCINES 78
TABLE 32 VACCINES MARKET SIZE FOR MENINGOCOCCAL DISEASE, BY REGION,
2014–2021 (USD MILLION) 79
TABLE 33 LIST OF POLIO VACCINES 80
TABLE 34 POLIO MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 80
TABLE 35 LIST OF ROTAVIRUS VACCINES 81
TABLE 36 VACCINES MARKET SIZE FOR ROTAVIRUS, BY REGION, 2014–2021 (USD MILLION) 81
TABLE 37 LIST OF HEPATITIS VACCINES 82
TABLE 38 VACCINES MARKET SIZE FOR HEPATITIS, BY REGION, 2014–2021 (USD MILLION) 83
TABLE 39 LIST OF MMR VACCINES 83
TABLE 40 VACCINES MARKET SIZE FOR MMR, BY REGION, 2014–2021 (USD MILLION) 84
TABLE 41 LIST OF VARICELLA VACCINES 84
TABLE 42 VACCINES MARKET SIZE FOR VARICELLA, BY REGION, 2014–2021 (USD MILLION) 84
TABLE 43 LIST OF OTHER VACCINES 86
TABLE 44 VACCINES MARKET SIZE FOR OTHER DISEASES, BY REGION,
2014–2021 (USD MILLION) 86
TABLE 45 VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 88
TABLE 46 VACCINES MARKET SIZE FOR PEDIATRICS, BY REGION, 2014–2021 (USD MILLION) 89
TABLE 47 NORTH AMERICA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY,
2014–2021 (USD MILLION) 89
TABLE 48 VACCINES MARKET SIZE FOR ADULTS, BY REGION, 2014–2021 (USD MILLION) 91
TABLE 49 NORTH AMERICA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY,
2014–2021 (USD MILLION) 91
TABLE 50 VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 94
TABLE 51 NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 96
TABLE 52 NORTH AMERICA: VACCINES MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 96
TABLE 53 NORTH AMERICA: VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 97
TABLE 54 NORTH AMERICA: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD MILLION) 97
TABLE 55 NORTH AMERICA: VACCINES MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 98
TABLE 56 U.S.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 99
TABLE 57 U.S.: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 99
TABLE 58 CANADA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 100
TABLE 59 CANADA: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 100
TABLE 60 EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 102
TABLE 61 EUROPE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 103
TABLE 62 EUROPE: VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 103
TABLE 63 EUROPE: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD MILLION) 103
TABLE 64 EUROPE: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 104
TABLE 65 GERMANY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 105
TABLE 66 U.K.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 106
TABLE 67 FRANCE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 107
TABLE 68 ITALY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 107
TABLE 69 SPAIN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 108
TABLE 70 ROE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 109
TABLE 71 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 & 2014 (USD) 111
TABLE 72 ASIA: VACCINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 111
TABLE 73 ASIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 112
TABLE 74 ASIA: VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 112
TABLE 75 ASIA: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD MILLION) 112
TABLE 76 ASIA: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 113
TABLE 77 JAPAN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 113
TABLE 78 CHINA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 114
TABLE 79 INDIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 115
TABLE 80 ROA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 116
TABLE 81 ROW: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 117
TABLE 82 ROW: VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 118
TABLE 83 ROW: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD MILLION) 118
TABLE 84 ROW: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 119
TABLE 85 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2013-2016 123
TABLE 86 REGULATORY APPROVALS, 2013-2016 124
TABLE 87 ACQUISITIONS, 2013-2016 125
TABLE 88 EXPANSIONS, 2013-2016 125
TABLE 89 OTHER DEVELOPMENTS, 2013-2016 126

LIST OF FIGURES

FIGURE 1 VACCINES MARKET SEGMENTATION 17
FIGURE 2 RESEARCH DESIGN 19
FIGURE 3 TOP-DOWN APPROACH 21
FIGURE 4 BOTTOM-UP APPROACH 22
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 22
FIGURE 6 DATA TRIANGULATION METHODOLOGY 23
FIGURE 7 VACCINES MARKET SIZE, BY TECHNOLOGY, 2016 VS. 2021 (USD MILLION) 28
FIGURE 8 GLOBAL VACCINES MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION) 28
FIGURE 9 GLOBAL VACCINES MARKET, BY DISEASE INDICATION, 2016 29
FIGURE 10 GLOBAL VACCINES MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION) 29
FIGURE 11 GLOBAL VACCINES MARKET, BY REGION, 2016 (USD MILLION) 30
FIGURE 12 HIGH PREVALENCE OF DISEASES AND RISING GOVERNMENT & NON-GOVERNMENT FUNDING FOR VACCINE DEVELOPMENT—PRIMARY GROWTH DRIVERS FOR THE GLOBAL VACCINES MARKET 31
FIGURE 13 MONOVALENT VACCINES SEGMENT TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD 32
FIGURE 14 PEDIATRICS SEGMENT TO DOMINATE THE VACCINES MARKET IN 2021 32
FIGURE 15 CONJUGATE VACCINES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016 33
FIGURE 16 U.S. TO DOMINATE THE VACCINES MARKET IN 2016 34
FIGURE 17 ASIA TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINES MARKET DURING THE FORECAST PERIOD 35
FIGURE 18 VACCINE MARKET SEGMENTATION 37
FIGURE 19 VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 38
FIGURE 20 INVESTORS PLAY AN IMPORTANT ROLE IN THE VACCINES MARKET 47
FIGURE 21 VACCINE FUNDING, BY INVESTOR, 2014 48
FIGURE 22 GAVI VACCINE FUNDING, BY TYPE OF INVESTOR, 2014 48
FIGURE 23 HIV PREVENTIVE VACCINES R&D FUNDING, BY INVESTOR, 2014 49
FIGURE 24 REGULATORY APPROVAL PROCESS FOR VACCINES 50
FIGURE 25 NORTH AMERICA ACCOUNTED FOR THE LARGEST NUMBER OF PATENT FILINGS
IN 2012 53
FIGURE 26 THE U.S. ACCOUNTED FOR LARGEST NUMBER OF PATENT FILINGS ACROSS THE GLOBE (2012) 54
FIGURE 27 CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINES MARKET DURING THE FORECAST PERIOD 58
FIGURE 28 ASIAN MARKET FOR LIVE ATTENUATED VACCINES TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 62
FIGURE 29 NORTH AMERICA IS EXPECTED TO DOMINATE THE RECOMBINANT VACCINES MARKET DURING THE FORECAST PERIOD 65
FIGURE 30 MONOVALENT VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET FROM 2016 TO 2021 67
FIGURE 31 NORTH AMERICA IS EXPECTED TO DOMINATE THE MULTIVALENT VACCINES MARKET DURING THE FORECAST PERIOD 70
FIGURE 32 PNEUMOCOCCAL DISEASE SEGMENT EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 72
FIGURE 33 ASIA IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE INFLUENZA DISEASE SEGMENT DURING THE FORECAST PERIOD 76
FIGURE 34 NORTH AMERICA TO DOMINATE THE MENINGOCOCCAL DISEASE MARKET DURING THE FORECAST PERIOD 79
FIGURE 35 ASIAN MARKET FOR HEPATITIS VACCINES TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 82
FIGURE 36 THE PEDIATRICS END-USER SEGMENT DOMINATES THE GLOBAL VACCINES MARKET IN 2016 88
FIGURE 37 ASIA TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINES MARKET FOR ADULTS DURING THE FORECAST PERIOD 90
FIGURE 38 GEOGRAPHIC SNAPSHOT (2016): EMERGING MARKETS TO OFFER GROWTH OPPORTUNITIES 93
FIGURE 39 GEOGRAPHIC BENCHMARKING FOR VACCINES TECHNOLOGY MARKET 94
FIGURE 40 NORTH AMERICA: VACCINES MARKET SNAPSHOT, 2016 95
FIGURE 41 EUROPE: VACCINES MARKET SNAPSHOT, 2016 101
FIGURE 42 ASIA: VACCINES MARKET SNAPSHOT, 2016 110
FIGURE 43 ORGANIC AND INORGANIC GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS FROM 2013 TO 2016 120
FIGURE 44 GLOBAL VACCINES MARKET SHARE, BY KEY PLAYER, 2015 121
FIGURE 45 BATTLE FOR MARKET SHARE: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS WERE THE PREFERRED STRATEGIES BY MARKET PLAYERS 122
FIGURE 46 PRODUCT BENCHMARKING FOR TOP 4 MARKET PLAYERS 127
FIGURE 47 PFIZER, INC.: COMPANY SNAPSHOT 128
FIGURE 48 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT 131
FIGURE 49 MERCK & CO., INC.: COMPANY SNAPSHOT 135
FIGURE 50 SANOFI PASTEUR: COMPANY SNAPSHOT 137
FIGURE 51 CSL LIMITED: COMPANY SNAPSHOT 140
FIGURE 52 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT 142
FIGURE 53 JOHNSON & JOHNSON: COMPANY SNAPSHOT 144
FIGURE 54 ASTRAZENECA : COMPANY SNAPSHOT 146
FIGURE 55 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT 148

当レポートのプレスリリースは発行されておりません。